In this issue:
- Sustained MRD negativity in newly diagnosed MM: impact of daratumumab
- Prognostic value of MRD negativity in MM
- Predicting early severe infections in newly diagnosed MM
- Infectious complications in relapsed/refractory MM after BCMA CAR T-cell therapy
- QOL, psychological distress and prognostic perceptions in MM
- Neurotoxicity in MM treated with ciltacabtagene autoleucel
- Ciltacabtagene autoleucel vs. conventional treatment for relapsed/refractory MM
- Adding isatuximab to pomalidomide and dexamethasone in relapsed/refractory MM
- Adding melflufen or pomalidomide to dexamethasone for lenalidomide-refractory MM
- Long-term outcomes of standard MM therapy in the real world
Download PDF